Literature DB >> 14504022

The effectiveness of combined naloxone/lofexidine in opiate detoxification: results from a double-blind randomized and placebo-controlled trial.

Tracy Beswick1, David Best, Jenny Bearn, Michael Gossop, Sian Rees, John Strang.   

Abstract

The efficacy of lofexidine/naloxone was compared with lofexidine/placebo in a double-blind, randomized, placebo-controlled trial in 89 opiate-dependent patients. There were no significant differences between the two groups in the proportion of patients completing detoxification or in the length of stay. Patients in the active naloxone group demonstrated gradual reductions in levels of withdrawal and craving over the detoxification period. At completion of detoxification, patients who received naloxone maintained a level of withdrawal consistently lower than that in the placebo group; however, naloxone did not substantially accelerate the resolution of the withdrawal syndrome. Implications for future research are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504022

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  6 in total

1.  Evidence-based addiction medicine: the use of lofexidine for opioid detoxification.

Authors:  Babatunde Adetunji; Maju Mathews; Adedapo Williams; Olusanya Rufai
Journal:  Psychiatry (Edgmont)       Date:  2004-11

Review 2.  Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?

Authors:  Timothy E Albertson; James Chenoweth; Jonathan Ford; Kelly Owen; Mark E Sutter
Journal:  J Med Toxicol       Date:  2014-12

3.  A role for the circadian transcription factor NPAS2 in the progressive loss of non-rapid eye movement sleep and increased arousal during fentanyl withdrawal in male mice.

Authors:  Mackenzie C Gamble; Byron Chuan; Teresa Gallego-Martin; Micah A Shelton; Stephanie Puig; Christopher P O'Donnell; Ryan W Logan
Journal:  Psychopharmacology (Berl)       Date:  2022-08-01       Impact factor: 4.415

Review 4.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

Review 5.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03

Review 6.  Pharmacological therapies for management of opium withdrawal.

Authors:  Afarin Rahimi-Movaghar; Jaleh Gholami; Laura Amato; Leila Hoseinie; Reza Yousefi-Nooraie; Masoumeh Amin-Esmaeili
Journal:  Cochrane Database Syst Rev       Date:  2018-06-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.